Braveheart Bio raises $382.5M in upsized Nasdaq IPO
What's the deal? Braveheart Bio priced its upsized initial public offering at $18.00 per share, selling 21,250,000 shares and raising gross proceeds of $382.5 million. The company will trade on the Nasdaq Global Market under the ticker BRVE from 6 August 2026.
Why now? The offering was upsized before pricing, and Braveheart Bio granted the underwriters a 30-day option to purchase up to 3,187,500 additional shares at the IPO price, less discounts and commissions. The offering is expected to close on 7 August 2026, subject to customary conditions.
What it means. The San Francisco-based clinical-stage biopharmaceutical company is developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead candidate, BHB-1893, is an oral cardiac myosin inhibitor being developed for obstructive and non-obstructive hypertrophic cardiomyopathy.
Who's backing it? Goldman SachsDealroom has a profile for this one. Try Dealroom →, JefferiesDealroom has a profile for this one. Try Dealroom →, TD Cowen, Stifel and Cantor FitzgeraldDealroom has a profile for this one. Try Dealroom → are acting as joint book-running managers. The registration statements became effective on 5 August 2026 and were filed with the US Securities and Exchange CommissionDealroom has a profile for this one. Try Dealroom →.
Read more: MarketScreener
Image credit: Braveheart Bio
